aap reports ?14.7 Million in H1 2009 Sales and an EBIT of -?0.4
Million
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ aap Implantate AG, a medical technology company listed in theFrankfurt Stock Exchange's Prime Standard, realized a 10% salesdecline to ?14.7 million in the first half of 2009 (previous year:?16.3 million), with an EBIT at -?0.4 million (previous year: ?1.7million). +----------------------------------------------------------------+ | In ? million | H1/2009 | H1/2008 | Change | |-----------------------+---------------+---------------+--------| | Sales | 14.7 | 16.3 | -10% | |-----------------------+---------------+---------------+--------| | EBITDA | 1.2 | 3.3 | -64% | |-----------------------+---------------+---------------+--------| | EBIT | -0.4 | 1.7 | n. a. | |-----------------------+---------------+---------------+--------| | EBT | -0.8 | 1.3 | n. a. | |-----------------------+---------------+---------------+--------| | Result for the period | -1.1 | 0.9 | n.a. | |-----------------------+---------------+---------------+--------| | In ? million | Jun. 30, 2009 | Dec. 31, 2008 | Change | |-----------------------+---------------+---------------+--------| | Equity (ratio) | 41.6 (65%) | 41.3 (62%) | +1% | |-----------------------+---------------+---------------+--------| | Balance sheet total | 64.3 | 67.0 | -4% | |-----------------------+---------------+---------------+--------| | Employees | 281 | 315 | -11% | +----------------------------------------------------------------+Group EBITDA in the first half of 2009 amounted to ?1.2 million(previous year: ?3.3 million). The Group's EBIT was -?0.4 million(previous year: ?1.7 million) and its EBT was -?0.8 million (previousyear: ?1.3 million). With a balance sheet total of ?64.3 million(Dec. 31, 2008: ?67.0 million) the equity ratio rose slightly to 65%.Disregarding one-time income (an initial order in 2008 and a productsale in 2009), the sales decline was only 3%.For the second half of 2009 the Management Board anticipates arecovery in demand and an improvement in sales and earnings.aap is currently holding promising talks on granting licenses or thedisposal of several products that no longer form part of its coreproduct area. In addition, global partner companies have expressedinterest in aap R&D projects.Along with these projects and higher anticipated sales than in thefiscal year2008, the improved cash flow situation and positiveresults of cost reduction measures are expected to contribute towardachieving profitable growth in the fiscal year 2009.aap Implantate AG's full report for the second quarter of 2009 isavailable to download from the Company's www.aap.de website.________________aap is a medical technology company that develops, manufactures andmarkets biomaterials and implants for traumatology and orthopedics.Its product portfolio includes bone cements, bone graft substitutes,antibiotic carriers, and implants for fracture healing and jointreplacement. In addition to its Berlin HQ the Company has sites inDieburg and Obernburg near Frankfurt am Main and Nijmegen in theNetherlands. aap Implantate AG has been listed in the Prime Standardsegment of the Frankfurt stock exchange since May 16, 2003.For queries please contact:aap Implantate AG, Nanette Hüdepohl, Head of CorporateCommunications, Lorenzweg 5, 12099 Berlin, GermanyTel.: +49 30 7501 9133, fax: +49 30 7501 9290, n.huedepohl(at)aap .deFor more about aap bio implants visit www.aap-bioimplants.com --- End of Message ---aap Implantate AGLorenzweg 5 Berlin GermanyWKN: 506660; ISIN: DE0005066609; Index: CDAX, Prime All Share, TECH All Share;Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Regulierter Markt in Frankfurter Wertpapierbörse;
Datum: 17.08.2009 - 10:10 Uhr
Sprache: Deutsch
News-ID 4777
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 365 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"aap reports ?14.7 Million in H1 2009 Sales and an EBIT of -?0.4
Million"
steht unter der journalistisch-redaktionellen Verantwortung von
aap Implantate AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
